Revlimid does not affect stem cell collection, study indicates

05/5/2013 | MyelomaBeacon.com

A study in the journal Supportive Care in Cancer found that initial therapy with Revlimid may not hamper the ability of patients with myeloma to produce enough stem cells to allow transplants. Only 2% of 319 patients were not able to produce adequate stem cells for a transplant. The researchers are urging a reassessment of guidelines from the International Myeloma Working Group that recommend that stem cell collection occur within four cycles of Revlimid treatment.

View Full Article in:

MyelomaBeacon.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA